HEARTWARE (NASDAQ: HTWR) upgraded to Outperform by Wells Fargo
Wells Fargo upgraded HEARTWARE (NASDAQ: HTWR) to Outperform. Previously, Wells
Fargo rated HEARTWARE (NASDAQ: HTWR) to Market Perform on 11/21/2012, when the stock price was valued at $86.25.
HeartWare International, Inc. (HeartWare), formerly HeartWare Limited, along with its subsidiaries, is a medical device company focused on developing small implantable pumps for the treatment of advanced heart failure. The Company?s product, the HeartWare Ventricular Assist System (the HeartWare System), includes a left ventricular assist device (LVAD), related accessories and surgical tools and is designed to provide circulatory support for patients with advanced heart failure. The core of the HeartWare System is a continuous flow blood pump, ventricular assist device (the HVAD Pump), a full-output device capable of pumping up to 10 liters of blood per minute. In January 2009, the HeartWare System received Conformite Europeene (CE) Marking, which allows for commercial sales in Europe and is the subject of an ongoing United States bridge-to-transplant clinical trial under an investigational device exemption (IDE) granted by the Food and Drug Administration of United States (FDA).
The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo
Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.